Literature DB >> 24985032

Histopathological difficulties in an adolescent lymphoma patient.

Ferenc Magyari1, Sándor Barna, Zsófia Miltényi, Hajnalka Rajnai, Judit Csomor, Miklós Udvardy, Árpad Illés, László Váróczy.   

Abstract

The B-cell lymphoma, unclassifiable, showing intermediate features typical for both diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (HL) is a novel category of diffuse large B-cell lymphomas (DLBCL/HL), which has been described by the WHO classification in 2008. This rare type of lymphomas, previously called as gray zone lymphoma presents peculiar clinical, morphological and immunophenotypical patterns. In December 2011 a 17-year old male was diagnosed with mixed cellularity subtype of classical HL. His clinical stage was IV/BXS (abdominal bulky) with unfavourable prognosis. Because of the unusually extended disease (nodal-extranodal-bulky) a histological revision was performed. After an incomplete course of ABVD chemotherapy the patient's symptoms disappeared and regression was detected in the size of peripheral lymph nodes. The diagnosis changed into DLBCL/HL, so the treatment was modified to R-CHOP-14 regimen. After the administration of 3 cycles of R-CHOP-14, he achieved a complete metabolic remission (CMR), which was confirmed by a (18)FDG-PET/CT scan. Receiving further 4 cycles of R-CHOP-14 therapy the patient was still in CMR, but a PET negative large mass (70 × 30 mm) still remained visible in the abdominal region. Considering this residuum and the aggressive subtype of lymphoma he was referred for an autologous hemopoietic stem cell transplantation (AHSCT). After 2 cycles of R-DHAP regimen, successful CD34 positive stem cell collection was performed in August 2012. In September 2012, he underwent a R-BEAM conditioning followed by AHSCT. The next (18)FDG-PET/CT still detected CMR 100 days after the AHSCT. The patient was in excellent clinical condition and also in complete remission 15 months after the AHSCT. Upon this case, it should be underlined that the diagnosis may need revision if a patient represents atypical clinical signs and behavior, and the importance of cooperation between clinicians and pathologists is also strongly emphasized.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24985032     DOI: 10.1007/s12253-014-9810-x

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  11 in total

1.  Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study.

Authors:  D Cazals-Hatem; M André; N Mounier; M C Copin; M Divine; F Berger; A Bosly; Y Kerneis; J Brière; B Quesnel; J Diebold; P Gaulard
Journal:  Am J Surg Pathol       Date:  2001-03       Impact factor: 6.394

2.  Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.

Authors:  M Rieger; A Österborg; R Pettengell; D White; D Gill; J Walewski; E Kuhnt; M Loeffler; M Pfreundschuh; A D Ho
Journal:  Ann Oncol       Date:  2010-08-19       Impact factor: 32.976

3.  Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.

Authors:  Theodoros P Vassilakopoulos; Gerassimos A Pangalis; Andreas Katsigiannis; Sotirios G Papageorgiou; Nikos Constantinou; Evangelos Terpos; Alexandra Zorbala; Effimia Vrakidou; Panagiotis Repoussis; Christos Poziopoulos; Zacharoula Galani; Maria N Dimopoulou; Stella I Kokoris; Sotirios Sachanas; Christina Kalpadakis; Evagelia M Dimitriadou; Marina P Siakantaris; Marie-Christine Kyrtsonis; John Dervenoulas; Meletios A Dimopoulos; John Meletis; Paraskevi Roussou; Panayiotis Panayiotidis; Photis Beris; Maria K Angelopoulou
Journal:  Oncologist       Date:  2012-01-26

Review 4.  Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?

Authors:  Cliona Grant; Kieron Dunleavy; Franziska C Eberle; Stefania Pittaluga; Wyndham H Wilson; Elaine S Jaffe
Journal:  Curr Hematol Malig Rep       Date:  2011-09       Impact factor: 3.952

5.  Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma.

Authors:  Robert P Hasserjian; German Ott; Kojo S J Elenitoba-Johnson; Olga Balague-Ponz; Daphne de Jong; Laurence de Leval
Journal:  J Hematop       Date:  2009-06-27       Impact factor: 0.196

Review 6.  Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma?

Authors:  Kieron Dunleavy; Cliona Grant; Franziska C Eberle; Stefania Pittaluga; Elaine S Jaffe; Wyndham H Wilson
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

7.  High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.

Authors:  H S Han; M P Escalón; B Hsiao; A Serafini; I S Lossos
Journal:  Ann Oncol       Date:  2008-10-07       Impact factor: 32.976

8.  Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Authors:  Pier Luigi Zinzani; Maurizio Martelli; Venerino Poletti; Umberto Vitolo; Paolo G Gobbi; Tommaso Chisesi; Giovanni Barosi; Andrés J M Ferreri; Monia Marchetti; Nicola Pimpinelli; Sante Tura
Journal:  Haematologica       Date:  2008-07-04       Impact factor: 9.941

9.  B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma without mediastinal disease: mimicking nodular sclerosis classical Hodgkin lymphoma.

Authors:  Noriko Iwaki; Yasuharu Sato; Toshiro Kurokawa; Yoshinobu Maeda; Kyotaro Ohno; Mai Takeuchi; Katsuyoshi Takata; Yorihisa Orita; Shinji Nakao; Tadashi Yoshino
Journal:  Med Mol Morphol       Date:  2013-03-20       Impact factor: 2.309

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  2 in total

1.  Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.

Authors:  Nobumasa Hojo; Makoto Nagasaki; Yasuha Mihara
Journal:  World J Clin Cases       Date:  2022-06-16       Impact factor: 1.534

2.  Transition Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma- Our Histopathological and Clinical Experience With Patients With Intermediate Lymphoma.

Authors:  Zsófia Simon; Bálint Virga; László Pinczés; Gábor Méhes; Zsófia Miltényi; Sándor Barna; Roxana Szabó; Árpád Illés
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.